JO3680B1 - تركيبات صيدلانية موضعية - Google Patents

تركيبات صيدلانية موضعية

Info

Publication number
JO3680B1
JO3680B1 JOP/2016/0097A JOP20160097A JO3680B1 JO 3680 B1 JO3680 B1 JO 3680B1 JO P20160097 A JOP20160097 A JO P20160097A JO 3680 B1 JO3680 B1 JO 3680B1
Authority
JO
Jordan
Prior art keywords
topical pharmaceutical
skin
pharmaceutical compositions
patient
relates
Prior art date
Application number
JOP/2016/0097A
Other languages
English (en)
Inventor
Roger Thomas Joey
D Lenn Jon
E Whiteman Justin
L Santos Leandro
D Sonti Sujatha
Quinn Doherty Michael
Bedard Mary
Jain Piyush
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56081527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3680(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Application granted granted Critical
Publication of JO3680B1 publication Critical patent/JO3680B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات مستحلبة صيدلانية موضعية تتضمن كمية فعالة علاجياً من 3، 5- ثاني هيدروكسي-4- أيزوبروبيل-ترانس- ستيلبين أو ملح مقبول صيدلانيا منه، طور زيتي، طور مائي، منشط للسطح، ومضاد للأكسدة، وفيها التركيب المستحلب عبارة عن مستحلب متجانس أو نشط والذي يذاب في طور الزيت. ويتعلق الاختراع أيضاً بطرق لعلاج حالات جلدية أو اضطراب الجلد في مريض بإعطاء التركيبات الحالية إلى جلد المريض
JOP/2016/0097A 2015-05-21 2016-05-19 تركيبات صيدلانية موضعية JO3680B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562165097P 2015-05-21 2015-05-21
US201662324450P 2016-04-19 2016-04-19

Publications (1)

Publication Number Publication Date
JO3680B1 true JO3680B1 (ar) 2020-08-27

Family

ID=56081527

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0097A JO3680B1 (ar) 2015-05-21 2016-05-19 تركيبات صيدلانية موضعية

Country Status (35)

Country Link
US (5) US10195160B2 (ar)
EP (2) EP3297605B1 (ar)
JP (4) JP6863904B2 (ar)
KR (2) KR20240090730A (ar)
CN (2) CN114042041B (ar)
AU (2) AU2016263161B2 (ar)
BR (1) BR112017024934A8 (ar)
CA (1) CA2986251A1 (ar)
CL (1) CL2017002939A1 (ar)
CO (1) CO2017011795A2 (ar)
CR (1) CR20170528A (ar)
CY (1) CY1125318T1 (ar)
DK (1) DK3297605T3 (ar)
DO (1) DOP2017000270A (ar)
EA (1) EA038624B1 (ar)
ES (1) ES2914112T3 (ar)
HR (1) HRP20220670T1 (ar)
HU (1) HUE059066T2 (ar)
IL (3) IL316851A (ar)
JO (1) JO3680B1 (ar)
LT (1) LT3297605T (ar)
MX (2) MX377629B (ar)
PE (1) PE20180038A1 (ar)
PH (1) PH12017502092A1 (ar)
PL (1) PL3297605T3 (ar)
PT (1) PT3297605T (ar)
RS (1) RS63402B1 (ar)
SG (1) SG11201708666RA (ar)
SI (1) SI3297605T1 (ar)
SM (1) SMT202200224T1 (ar)
TW (1) TWI705831B (ar)
UA (1) UA125500C2 (ar)
UY (1) UY36682A (ar)
WO (1) WO2016185428A1 (ar)
ZA (1) ZA202007965B (ar)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US11617724B2 (en) * 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
IL316851A (en) * 2015-05-21 2025-01-01 Dermavant Sciences GmbH Preparations that are pharmaceutical emulsions for topical use containing 5,3-dihydroxy-4-isopropyl-trans-stilbene and their use for the treatment or prevention of dermatological conditions or disorders
CA3082115A1 (en) * 2017-11-10 2019-05-16 Dermavant Sciences GmbH Process for preparing tapinarof
CN109085257B (zh) * 2018-07-05 2021-04-06 中央民族大学 一种同时定量检测小鼠血浆中黄芪甲苷-iv、环黄芪醇的方法
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
JP6898622B2 (ja) * 2019-01-30 2021-07-07 学校法人神奈川大学 皮膚又は粘膜の外用剤及びその製造方法、並びに皮膚又は粘膜の外用剤の基剤
EP4252844A3 (en) * 2019-04-17 2023-12-06 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
FI3968997T3 (fi) * 2019-05-15 2026-06-09 Leo Pharma As Delgositinibin formulaatio voiteen muodossa
US20200383887A1 (en) * 2019-06-04 2020-12-10 L'oreal Oxygenate skin treatment system
US11807810B2 (en) 2019-06-26 2023-11-07 Locus Solutions Ipco, Llc Multi-functional compositions comprising concentrated acids for enhanced oil and gas recovery
KR20220041125A (ko) * 2019-07-24 2022-03-31 솔-겔 테크놀로지스 리미티드 국부 타피나로프-egfr 억제제 조성물을 이용한 피부 장애의 치료
WO2021059283A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of cutaneous adverse effects caused by oncological therapy with topical tapinarof compositions
WO2021059281A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
CA3160126A1 (en) * 2019-11-06 2021-05-14 Sol-Gel Technologies Ltd. Method of treating palmoplantar keratoderma
EP4061332A4 (en) * 2019-11-24 2023-11-29 Sol-Gel Technologies Ltd. TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR
GB202000167D0 (en) * 2020-01-07 2020-02-19 Cytovation As Composition for treatment of neoplastic lesions
US11154486B2 (en) 2020-02-14 2021-10-26 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11191708B2 (en) * 2020-02-17 2021-12-07 William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions
CA3183195A1 (en) * 2020-06-24 2021-12-30 Piyush Jain Topical pharmaceutical compositions
IL298928A (en) * 2020-06-30 2023-02-01 Dermira Inc RORγt INHIBITORS AND TOPICAL USES THEREOF
US12440529B2 (en) 2020-09-22 2025-10-14 Alphyn Biologics, Inc. Topical Croton lechleri compositions and their use in the treatment of a bacterial colonization or primary or secondary bacterial infection of an underlying skin disorder
CN116723864A (zh) * 2020-11-23 2023-09-08 德玛万科学有限责任公司 Tapinarof的凝胶、软膏和泡沫配制剂及使用方法
JP2024506953A (ja) * 2021-02-17 2024-02-15 ダーマバント、サイエンシーズ、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング Ｐｌａｑｕｅ乾癬、アトピー性皮膚炎、放射線性皮膚炎の治療におけるタピナロフの改善効果
AU2022226676A1 (en) * 2021-02-25 2023-09-28 Alphyn Biologics, Llc Composition for treatment of topical dermatological bacterial skin conditions
CN113797159A (zh) * 2021-10-22 2021-12-17 冠昊生物科技股份有限公司 一种本维莫德乳膏剂及其制备方法和用途
JP2025529076A (ja) * 2022-08-30 2025-09-04 ダーマヴァント サイエンシーズ ゲーエムベーハー ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
JP2026501135A (ja) * 2022-12-08 2026-01-14 ヘアダオ ペイメンツ エルエルシー 脱毛及び白髪の治療又は予防のための局所組成物
WO2025031935A1 (en) 2023-08-04 2025-02-13 Sandoz Ag Crystalline forms of tapinarof
AU2024371477A1 (en) 2023-11-02 2026-04-16 Thederma Shanghai Co., Ltd. Pharmaceutical composition of phenol derivative having improved stability and use thereof
WO2026090700A1 (pt) * 2024-10-29 2026-05-07 Chemyunion Ltda Composição para condicionamento de fibras; usos e métodos relacionados

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5111748A (en) 1974-07-16 1976-01-30 Taisho Pharmaceutical Co Ltd Suchirubenjudotaino seizoho
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
JPS58159410A (ja) 1982-03-18 1983-09-21 Mitsubishi Chem Ind Ltd 抗炎症剤
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5008100A (en) 1989-08-11 1991-04-16 Elizabeth Arden Co., Division Of Conopco, Inc. Oil-in-water emulsions containing polyethylene
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
AU7513994A (en) 1993-07-27 1995-02-28 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria (xenorhabdus) and (photorhabdus) spp.
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JPH1072330A (ja) 1996-09-03 1998-03-17 Kansai Kouso Kk チロシナーゼ活性阻害剤及び化粧料
JPH1143436A (ja) * 1997-07-25 1999-02-16 Showa Denko Kk 末梢血流障害予防・治療剤
US6210693B1 (en) 1998-02-10 2001-04-03 Shiseido Company, Ltd. Oil-in-water type emulsified composition
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
FR2777183B1 (fr) 1998-04-10 2001-03-02 Oreal Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant
AU4084599A (en) 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
DE19842730A1 (de) * 1998-09-18 2000-03-23 Beiersdorf Ag Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl
FR2785284B1 (fr) 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US20020054895A1 (en) * 1999-07-23 2002-05-09 Alwyn Company, Inc. Allantoin-containing skin cream
ATE444960T1 (de) * 1999-12-06 2009-10-15 Welichem Biotech Inc Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
US7321050B2 (en) * 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
FR2811564B1 (fr) * 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US20040102517A1 (en) 2001-01-18 2004-05-27 Genhui Chen Novel1,2-diphenylethene derivatives for treatment of immune diseases
WO2003009807A2 (en) 2001-07-23 2003-02-06 Galileo Laboratories, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
RU2212763C2 (ru) * 2001-08-16 2003-09-20 Общество с ограниченной ответственностью "Подсолнечник Технологии" Система открытой оптической связи
AU2003218121A1 (en) * 2002-03-12 2003-09-29 Playtex Products, Inc. Lotion compositions
US20040202634A1 (en) * 2003-03-19 2004-10-14 L'oreal Composition useful for cosmetic or dermatological use containing a block copolymer
WO2005087195A2 (en) 2004-03-18 2005-09-22 Panacea Biotec Ltd. Novel compositions for topical delivery
US20060018861A1 (en) * 2004-07-23 2006-01-26 Minghua Chen Skin care composition
ATE402740T1 (de) * 2004-10-19 2008-08-15 Boots Co Plc Kosmetische zusammensetzungen
US20060246098A1 (en) * 2005-03-16 2006-11-02 Srinivasa Rao Stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same
KR20070057660A (ko) * 2005-12-01 2007-06-07 롬 앤드 하아스 컴패니 활성물을 안정시키기 위한 수성 폴리머 분산액
FR2898498B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
AU2007356328A1 (en) * 2006-11-14 2009-01-15 Tal Berman Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
EP1930499A1 (en) * 2006-12-08 2008-06-11 Cognis IP Management GmbH Tissue paper comprising a softening lotion
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2009108762A2 (en) 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US8226965B2 (en) * 2008-04-25 2012-07-24 Nanobio Corporation Methods of treating fungal, yeast and mold infections
JP2009291133A (ja) * 2008-06-05 2009-12-17 Snow Brand Milk Prod Co Ltd チーズ食品
WO2010096868A1 (en) * 2009-02-25 2010-09-02 Stiefel Research Australia Pty Ltd Topical foam composition
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
CN101822638A (zh) * 2009-12-01 2010-09-08 河北科技大学 二苯乙烯类化合物的纳米乳及其制备方法
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
JP2013521251A (ja) * 2010-03-01 2013-06-10 フォトキュア エイエスエイ 美容組成物
MX2013004296A (es) * 2010-10-21 2013-09-26 Cadila Healthcare Ltd Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis.
DK2645993T3 (en) 2010-12-03 2017-02-13 Allergan Inc Pharmaceutical cream compositions comprising oxymetazoline
BR112013033617B1 (pt) 2011-06-27 2021-10-26 Galderma Research & Development Uso de mrna, método para o diagnóstico de acne, métodos para o monitoramento da progressão ou variação de acne e da eficácia de um tratamento para tratar acne, e de triagem in vitro para a identificação de inibidores de diferenciação de células th17
WO2013130535A1 (en) 2012-02-27 2013-09-06 Newgen Biopharma Corporation Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
CN102657610A (zh) 2012-05-11 2012-09-12 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯微乳剂及其制备方法
CN102657602B (zh) 2012-05-22 2013-08-07 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法
US9433680B2 (en) * 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CN103315958B (zh) 2013-07-19 2014-10-29 河北科技大学 苯烯莫德纳米乳及其制备方法
WO2015085143A2 (en) 2013-12-06 2015-06-11 Stc.Unm Therapeutic agents for skin diseases and conditions
CN103992212B (zh) * 2014-05-29 2015-07-01 河北科技大学 顺式苯烯莫德的合成方法及顺式苯烯莫德的应用
KR102607222B1 (ko) 2014-12-12 2023-11-29 더마반트 사이언시즈 게엠베하 신규 사용 방법
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
IL316851A (en) 2015-05-21 2025-01-01 Dermavant Sciences GmbH Preparations that are pharmaceutical emulsions for topical use containing 5,3-dihydroxy-4-isopropyl-trans-stilbene and their use for the treatment or prevention of dermatological conditions or disorders
CA3082115A1 (en) 2017-11-10 2019-05-16 Dermavant Sciences GmbH Process for preparing tapinarof

Also Published As

Publication number Publication date
IL255203A0 (en) 2017-12-31
EP4094752A1 (en) 2022-11-30
AU2016263161A1 (en) 2017-11-16
CY1125318T1 (el) 2024-12-13
AU2016263161B2 (en) 2019-02-28
US20160338973A1 (en) 2016-11-24
JP7864160B2 (ja) 2026-05-22
CO2017011795A2 (es) 2018-02-28
EP3297605A1 (en) 2018-03-28
IL255203B (en) 2021-05-31
UA125500C2 (uk) 2022-04-13
US20190151255A1 (en) 2019-05-23
EA201792559A1 (ru) 2018-04-30
PE20180038A1 (es) 2018-01-09
HK1245074A1 (en) 2018-08-24
CA2986251A1 (en) 2016-11-24
MX2017014804A (es) 2018-02-15
UY36682A (es) 2016-12-30
JP2023113829A (ja) 2023-08-16
US20200101027A1 (en) 2020-04-02
WO2016185428A1 (en) 2016-11-24
US10195160B2 (en) 2019-02-05
BR112017024934A8 (pt) 2021-03-30
TWI705831B (zh) 2020-10-01
PL3297605T3 (pl) 2022-07-11
SI3297605T1 (sl) 2022-08-31
IL316851A (en) 2025-01-01
US11612573B2 (en) 2023-03-28
DOP2017000270A (es) 2017-12-15
CR20170528A (es) 2018-01-22
NZ736602A (en) 2024-10-25
LT3297605T (lt) 2022-06-27
US11622945B2 (en) 2023-04-11
EP3297605B1 (en) 2022-05-04
CN114042041A (zh) 2022-02-15
AU2019203627A1 (en) 2019-06-13
KR20240090730A (ko) 2024-06-21
CN107666902A (zh) 2018-02-06
US11458108B2 (en) 2022-10-04
CN114042041B (zh) 2023-08-22
KR20180008490A (ko) 2018-01-24
US20190192445A1 (en) 2019-06-27
KR102669247B1 (ko) 2024-05-27
BR112017024934A2 (pt) 2018-07-31
JP6863904B2 (ja) 2021-04-21
IL282304A (en) 2021-05-31
SMT202200224T1 (it) 2022-07-21
ES2914112T3 (es) 2022-06-07
IL282304B1 (en) 2024-12-01
JP2018515561A (ja) 2018-06-14
MX2020012595A (es) 2021-02-09
AU2019203627B2 (en) 2020-12-24
SG11201708666RA (en) 2017-12-28
HUE059066T2 (hu) 2022-10-28
EA038624B1 (ru) 2021-09-24
DK3297605T3 (da) 2022-06-07
JP7531658B2 (ja) 2024-08-09
MX377629B (es) 2025-03-10
JP2024153800A (ja) 2024-10-29
PT3297605T (pt) 2022-05-30
JP2021105027A (ja) 2021-07-26
CL2017002939A1 (es) 2018-03-16
RS63402B1 (sr) 2022-08-31
ZA202007965B (en) 2022-12-21
CN107666902B (zh) 2021-09-21
PH12017502092A1 (en) 2018-05-07
HRP20220670T1 (hr) 2022-08-19
US10426743B2 (en) 2019-10-01
TW201705940A (zh) 2017-02-16
IL282304B2 (en) 2025-04-01
US20190192446A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
PH12017502092A1 (en) Topical pharmaceutical compositions
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
BR102016017090B8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112021025701A2 (pt) Formulações e métodos de parasiticida de isoxazolina para tratar blefarite
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MX377919B (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
ZA201904591B (en) Dexmedetomidine or medetomidine for use in treating separation anxiety in dogs
MX2021007161A (es) Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia.
MX2019003470A (es) Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
MX381515B (es) Composición farmacéutica que comprende nebivolol con tasa de disolución mejorada
EA201792170A1 (ru) Производные индола
CL2018003268A1 (es) Ácidos carboxílicos para tratar/prevenir una enfermedad de la piel.
AR104699A1 (es) Composición farmacéutica tópica en emulsión y su uso para fabricar un medicamento
UA106472U (uk) Засіб для лікування дерматологічних захворювань
UA106471U (uk) Засіб для лікування дерматологічних захворювань
TH166182A (th) "สารผสมทางเภสัชกรรมสำหรับการป้องกันหรือบำบัดรักษาผื่นผิวหนัง"